Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Feasibility Study of PEAR-002b, a Novel Prescription Digital Therapeutic to Support Unobserved Buprenorphine Initiation and Adherence in Opioid Use Disorder Outpatients

NCT05412966 is registered in ClinicalTrials.gov with Pear Therapeutics, Inc. as lead sponsor.

NCT NCT05412966
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05412966 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Feasibility Study of PEAR-002b, a Novel Prescription Digital Therapeutic to Support Unobserved Buprenorphine Initiation and Adherence in Opioid Use Disorder Outpatients
Lead sponsor
Pear Therapeutics, Inc.
Phase
Not applicable
Overall status
Completed
Start date
November 4, 2022
Completion date
December 16, 2022
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

opioid use disorder